Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Partnership
Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...
Product Name : PB2452
Product Type : Antibody
Upfront Cash : Undisclosed
November 05, 2023
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Agreement
Details :
Product Name : ACH000029
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : McQuade Center for Strategic Research and Development
Deal Size : Undisclosed
Deal Type : Agreement